AGONISTS OF DDAH1 FOR TREATING ENDOTHELIAL DYSFUNCTION
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
N/A
Issued Date -
May 26, 2016
app pub date -
Jun 17, 2014
filing date -
Jun 17, 2013
priority date (Note) -
Abandoned
status (Latency Note)
Importance
Abstract
The present invention derives from the finding that expression of DDAH1 is heavily post-transcriptionally regulated by microRNAs. By preventing or blocking the interaction between such microRNAs and the DDAH1 mRNA, the production of DDAH1 protein can be increased. This has utility in the prevention or treatment of diseases and disorders that are associated with reduced DDAH1 levels or increased ADMA levels, such as diseases or disorders that are characterised by endothelial dysfunction.
First Claim
Family
International Classification(s)
Cited Art Landscape
Patent Citation Ranking
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully